LGVNLongeveron Inc - Ordinary Shares - Class A
Compact View
Earnings Recap
• Reported GAAP EPS of -$0.19 up 44.12% YoY • Reported revenue of $0.4M up 4.46% YoY • Longeveron expects its cash and cash equivalents as of March 31, 2026, including Private Placement proceeds, will fund operations into the fourth quarter of 2026, but additional financing will be required. Longeveron anticipates continued operating losses and increased spending.
Bullish
Longeveron's AD program received RMAT and Fast Track designations, and a private placement raised $15.5M in financing. The HLHS ELPIS II trial completed enrollment, with results expected in August 2026, and a pediatric DCM Phase 2 trial is planned.
Bearish
Longeveron faces substantial doubt about its going concern ability due to insufficient cash and funding challenges. The FDA deemed the HLHS trial's primary endpoint inappropriate, and contract manufacturing revenue declined significantly from a single customer.